Crossmark

Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?

Crossref DOI link: https://doi.org/10.1038/s41409-023-01997-3

Published Online: 2023-05-08

Published Print: 2023-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Konuma, Takaaki https://orcid.org/0000-0002-1496-376X
Itonaga, Hidehiro

Ishiyama, Ken https://orcid.org/0000-0002-6189-0620
Doki, Noriko

Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Sawa, Masashi

Katayama, Yuta https://orcid.org/0000-0001-5054-9104
Tanaka, Masatsugu

Ueda, Yasunori

Onizuka, Makoto https://orcid.org/0000-0003-3864-0823
Miyakoshi, Shigesaburo

Ozawa, Yukiyasu

Fukuda, Takahiro

Matsuoka, Ken-ichi https://orcid.org/0000-0001-7955-8266
Tanaka, Junji

Kimura, Takafumi

Ichinohe, Tatsuo https://orcid.org/0000-0002-0393-4066
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
License Information

Text and Data Mining valid from 2023-05-08

Version of Record valid from 2023-05-08
More Information

Article History

Received: 23 February 2023

Revised: 13 April 2023

Accepted: 19 April 2023

First Online: 8 May 2023

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below